In contrast, CTRP3, CTRP9, CTRP12, and CTRP13 activate anti-inflammatory and anti-atherosclerotic mechanisms of CAD, by inhibiting endothelial inflammation and reducing plaque formation (mediated via inhibition of both inflammatory cytokine secretion and expression of adhesion molecules). The gene discussed is C1QTNF9; the disease is coronary artery disorder.